Archive correction — 14 October 2026. The original headline and body described UK IPO and acquisition exits as blocked across the market. The article did not establish that conclusion. Unsupported secondary-market price bands and reopening forecasts have been removed. Original publication dates are retained.
Assess an exit route at company level
ObvioTech analysis: an exit depends on the company, potential buyers, financial position, transaction terms and market conditions. A difficult transaction or weak market period does not establish that no UK IPO or acquisition can occur. The London Stock Exchange maintains a record of new issues; those records must also be distinguished from a dataset specifically covering venture-backed technology exits. Exchange new-issues information.
A useful assessment should state its population and period. Completed deals, announced deals, withdrawals and private discussions are different evidence. The earlier claims that virtually every company above a revenue threshold starts in New York and that all UK exit channels are unavailable were not demonstrated.
Do not use a standard NSI delay for every deal
The 2025/26 NSI annual report records that 95.6% of reviewed notifications needed no further action; 4.4% were called in. The initial statutory review and a further called-in assessment are different stages. This evidence does not support a universal twelve-to-thirty-week clearance period, nor does nationality alone determine whether a transaction is in scope. Official report.
The government published a response on refinements to the notification rules on 12 March 2026. A proposal or response is distinct from commenced legislation, but it contradicts the earlier assertion that no sector-definition review was planned. Government announcement.
PISCES: a possible mechanism, not guaranteed liquidity
The FCA describes PISCES as a framework for intermittent trading of private-company shares and lists approved operators. Approval of an operator does not guarantee a buyer, a particular price or a successful exit. Participation and investor eligibility have conditions. FCA explanation and operator list.
The article has no verified dataset establishing that institutional investors have universally refused PISCES or that every portfolio company can use it. Assess the specific venue, company arrangements, trading event and risks.
Questions for founders and fund managers
- Which routes are feasible for this company and why?
- What evidence supports the proposed valuation and buyer demand?
- Which regulatory approvals, shareholder consents and contractual restrictions apply?
- How would timing affect cash needs, fund terms and tax treatment?
- What contingency remains if the transaction does not complete?
These are ObvioTech planning questions, not a recommendation to sell, retain or buy a particular investment. There is no universal acceptable discount to carrying value or reopening date. A fund extension or continuation transaction depends on its documents and circumstances; obtain appropriate professional advice.
